Haemonetics rises as CSL sets 2027 timeline for plasma-device rollout
+17.46% to $119.47 from $101.71
What moved HAE
- Haemonetics shares gained roughly 8% in premarket trading after news that CSL expects to complete the rollout of Haemonetics’ plasmapheresis platform across its U.S. plasma-collection centers by the end of 2027.
- The rollout builds on a non-exclusive supply agreement signed in August under which CSL Plasma can use Haemonetics’ NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S.
- Haemonetics had previously lost CSL’s plasma-collection business when an earlier device contract expired in 2022 and was not renewed, with CSL shifting to a competitor’s systems.
Sources: CNBC · MassDevice